Literature DB >> 33763363

Characteristic of Tumor Regrowth After Gamma Knife Radiosurgery and Outcomes of Repeat Gamma Knife Radiosurgery in Nonfunctioning Pituitary Adenomas.

Yanli Li1, Lisha Wu2, Tingting Quan3, Junyi Fu4, Linhui Cao5, Xi Li6, Shunyao Liang7, Minyi Huang7, Yinhui Deng7, Jinxiu Yu7.   

Abstract

OBJECTIVE: This study aimed to report the characteristic of tumor regrowth after gamma knife radiosurgery (GKRS) and outcomes of repeat GKRS in nonfunctioning pituitary adenomas (NFPAs). DESIGN AND METHODS: This retrospective study consisted of 369 NFPA patients treated with GKRS. The median age was 45.2 (range, 7.2-84.0) years. The median tumor volume was 3.5 (range, 0.1-44.3) cm3.
RESULTS: Twenty-four patients (6.5%) were confirmed as regrowth after GKRS. The regrowth-free survivals were 100%, 98%, 97%, 86% and 77% at 1, 3, 5, 10 and 15 year, respectively. In multivariate analysis, parasellar invasion and margin dose (<12 Gy) were associated with tumor regrowth (hazard ratio [HR] = 3.125, 95% confidence interval [CI] = 1.318-7.410, p = 0.010 and HR = 3.359, 95% CI = 1.347-8.379, p = 0.009, respectively). The median time of regrowth was 86.1 (range, 23.2-236.0) months. Previous surgery was associated with tumor regrowth out of field (p = 0.033). Twelve patients underwent repeat GKRS, including regrowth in (n = 8) and out of field (n = 4). Tumor shrunk in seven patients (58.3%), remained stable in one (8.3%) and regrowth in four (33.3%) with a median repeat GKRS margin dose of 12 (range, 10.0-14.0) Gy. The actuarial tumor control rates were 100%, 90%, 90%, 68%, and 68% at 1, 3, 5, 10, and 15 years after repeat GKRS, respectively.
CONCLUSIONS: Parasellar invasion and tumor margin dose (<12 Gy) were independent risk factors for tumor regrowth after GKRS. Repeat GKRS might be effective on tumor control for selected patients. For regrowth in field due to relatively insufficient radiation dose, repeat GKRS might offer satisfactory tumor control. For regrowth out of field, preventing regrowth out of field was the key management. Sufficient target coverage and close follow-up might be helpful.
Copyright © 2021 Li, Wu, Quan, Fu, Cao, Li, Liang, Huang, Deng and Yu.

Entities:  

Keywords:  aggressive; gamma knife; nonfunctioning; pituitary adenoma; radiosurgery; regrowth

Year:  2021        PMID: 33763363      PMCID: PMC7982800          DOI: 10.3389/fonc.2021.627428

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  28 in total

Review 1.  Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Primary Management of Patients With Nonfunctioning Pituitary Adenomas.

Authors:  Joshua William Lucas; Mary E Bodach; Luis M Tumialan; Nelson M Oyesiku; Chirag G Patil; Zachary Litvack; Manish K Aghi; Gabriel Zada
Journal:  Neurosurgery       Date:  2016-10       Impact factor: 4.654

Review 2.  Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for the Management of Patients With Residual or Recurrent Nonfunctioning Pituitary Adenomas.

Authors:  Jason Sheehan; Cheng-Chia Lee; Mary E Bodach; Luis M Tumialan; Nelson M Oyesiku; Chirag G Patil; Zachary Litvack; Gabriel Zada; Manish K Aghi
Journal:  Neurosurgery       Date:  2016-10       Impact factor: 4.654

Review 3.  How and when to use temozolomide to treat aggressive pituitary tumours.

Authors:  Ben C Whitelaw
Journal:  Endocr Relat Cancer       Date:  2019-08       Impact factor: 5.678

4.  Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

Authors:  Gérald Raverot; Nathalie Sturm; Florence de Fraipont; Marie Muller; Sylvie Salenave; Philippe Caron; Olivier Chabre; Philippe Chanson; Christine Cortet-Rudelli; Richard Assaker; Henry Dufour; Stephan Gaillard; Patrick François; Emmanuel Jouanneau; Jean-Guy Passagia; Michèle Bernier; Aurélie Cornélius; Dominique Figarella-Branger; Jacqueline Trouillas; Françoise Borson-Chazot; Thierry Brue
Journal:  J Clin Endocrinol Metab       Date:  2010-07-21       Impact factor: 5.958

5.  Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.

Authors:  Hélène Lasolle; Christine Cortet; Fréderic Castinetti; Lucie Cloix; Philippe Caron; Brigitte Delemer; Rachel Desailloud; Christel Jublanc; Christine Lebrun-Frenay; Jean-Louis Sadoul; Luc Taillandier; Marie Batisse-Lignier; Fabrice Bonnet; Nathalie Bourcigaux; Damien Bresson; Olivier Chabre; Philippe Chanson; Cyril Garcia; Magalie Haissaguerre; Yves Reznik; Sophie Borot; Chiara Villa; Alexandre Vasiljevic; Stephan Gaillard; Emmanuel Jouanneau; Guillaume Assié; Gérald Raverot
Journal:  Eur J Endocrinol       Date:  2017-06       Impact factor: 6.664

6.  Clinical and Radiologic Outcome of Gamma Knife Radiosurgery on Nonfunctioning Pituitary Adenomas.

Authors:  Shyamal C Bir; Richard D Murray; Sudheer Ambekar; Papireddy Bollam; Anil Nanda
Journal:  J Neurol Surg B Skull Base       Date:  2015-05-08

7.  Gamma knife radiosurgery for pituitary adenoma: early results.

Authors:  Zbigniew Petrovich; Cheng Yu; Steven L Giannotta; Chi-Shing Zee; Michael L J Apuzzo
Journal:  Neurosurgery       Date:  2003-07       Impact factor: 4.654

8.  Adjuvant Gamma Knife radiosurgery in non-functioning pituitary adenomas; low risk of long-term complications in selected patients.

Authors:  Charlotte Höybye; Tiit Rähn
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

9.  Gamma Knife surgery for patients with nonfunctioning pituitary macroadenomas: predictors of tumor control, neurological deficits, and hypopituitarism.

Authors:  Robert M Starke; Brian J Williams; John A Jane; Jason P Sheehan
Journal:  J Neurosurg       Date:  2012-05-11       Impact factor: 5.115

10.  Efficacy of gamma knife radiosurgery for nonfunctioning pituitary adenomas: a quantitative follow up with magnetic resonance imaging-based volumetric analysis.

Authors:  Berndt Wowra; Walter Stummer
Journal:  J Neurosurg       Date:  2002-12       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.